Home | About PR | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |   Login 
Pharmacognosy Magazine
Search Article 
Advanced search 

 Table of Contents 
Year : 2016  |  Volume : 8  |  Issue : 3  |  Page : 176-180  

Effects of five Bangladeshi plant extracts on In vitro thrombolysis and cytotoxicity

1 Department of Pharmacy, BGC Trust University, Chittagong-4000, Bangladesh
2 Department of Pharmacy, BGC Trust University Bangladesh, Chittagong-4000; Department of Biochemistry and Molecular Biology, University of Chittagong, Chittagong-4331, Bangladesh
3 Department of Pharmacy, Southeast University, Banani, Dhaka-1213, Bangladesh
4 Department of Pharmacy, University of Chittagong, Chittagong-4331, Bangladesh

Date of Web Publication24-May-2016

Correspondence Address:
Mir Muhammad Nasir Uddin
Department of Pharmacy, Faculty of Biological Science, University of Chittagong, Chittagong-4331
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-8490.181403

Rights and Permissions

Background: Piper Betle, Pterospermum acerifolium, Saraca indica, Argyreia speciosa, and Rhaphidophora glauca are medicinal plants commonly used as traditional medicine for the treatment of various diseases. To examine, whether organic extracts of these plants possess thrombolytic properties with minimal or no toxicity is our main aim of the study. Materials and Methods: In vitro thrombolytic model was used to check the clot lysis effects using streptokinase (SK) as a positive control and water as a negative control. Cytotoxicity was screened by brine shrimp lethality bioassay using vincristine sulfate (VS) as positive control. Results: Among herbal drugs, different organic extracts of P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca showed significant (P < 0.05 and P < 0.0001) clot lysis activity viz., 31.58% ±0.76%, 40.50% ±0.94%, 49.70% ±1.69%, 35.81% ±0.86%, and 43.80% ±0.91%, respectively, compared to reference drug SK (79.32% ±1.629%). In brine shrimp cytotoxic assay, mortality achieved by the extracts showed lethal concentration 50 (LC50) values 274.64 ± 3.46, 215.60 ± 4.59, 478.40 ± 6.98, 233.37 ± 2.56, and 209.32 ± 1.98 μg/ml, respectively, with reference to VS (LC50,0.05 ± 0.34). Conclusion: In this study, S. indica, R. glauca, and P. acerifolium possessed effective thrombolytic activity. Further studies can be undertaken to identify certain structure of the ingredients in the extracts and to elucidate the precise mechanism of action.

  • Five Bangladesh medicinal plants, named Piper betle, Pterospermum acerifolium, Saraca indica, Argyreia speciosa, and Rhaphidophora glauca were subjected to comparative antithrombotic and toxicity based analysis. In comparative study, Saraca indica showed highest clot lysis (49.70 ± 1.69%) activity among the other plant with lowest toxicity (LC50: 478.40 ± 6.98)

Abbreviations Used: h: Hour; min: Minutes; sec: Second; kg: Kilogram; g: Gram; μg: Microgram; L: Liter; mL: Millilitre; μL: Micro liter; μg/mL: Microgram per Milliliter; mg/kg: Milligram per kilogram; %: Percent; °C: Degree Celsius; et al.: et alliori (and others); w/w: Weight by Weight; v/v: Volume by Volume; SEM: Standard Error Mean; LC50: lethal concentration at 50%

Keywords: Argyreia speciosa, Piper betle, Pterospermum acerifolium, Rhaphidophora glauca, Saraca indica, thrombolysis

How to cite this article:
Dash R, Emran TB, Paul A, Siddique MK, Khan MA, Rahman MG, Sarwar MS, Nasir Uddin MM. Effects of five Bangladeshi plant extracts on In vitro thrombolysis and cytotoxicity. Phcog Res 2016;8:176-80

How to cite this URL:
Dash R, Emran TB, Paul A, Siddique MK, Khan MA, Rahman MG, Sarwar MS, Nasir Uddin MM. Effects of five Bangladeshi plant extracts on In vitro thrombolysis and cytotoxicity. Phcog Res [serial online] 2016 [cited 2021 Apr 18];8:176-80. Available from: http://www.phcogres.com/text.asp?2016/8/3/176/181403

   Introduction Top

Thrombosis is one of the three major causes of cardiovascular morbidity and mortality in the current world.[1] In simple words, thrombosis means localized clotting of the blood, which can take place within the arterial or the venous circulation and contains a significant medical impact.[2] Acute arterial thrombosis would be the proximal reason for many instances of myocardial infarction (stroke) in addition to about 80% of strokes. Venous thromboembolism is also the third leading reason behind cardiovascular-associated death.[3] The pathophysiology of arterial thrombosis is different from that of venous thrombosis as reflected because of the other ways in which these are treated. In broad terms, arterial thrombosis is given drugs that target platelets, and venous thrombosis is treated with drugs that target proteins in the coagulation cascade.[4],[5] The accessible antithrombotic medicine is able at reducing arterial thrombosis and venous thrombosis in patients with heart problems. But these synthetic drugs cause bleeding, which limits their use and urge to discover new anticoagulant, antiplatelet and profibrinolytic agents from natural sources.[6],[7] Although, due to low cost, urokinase, streptokinase (SK), or tissue plasminogen activators have been used as clinical thrombolytic agent for the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas [8] in India, Bangladesh, and other developing countries in comparison to other thrombolytic drugs but restricted in some patients as a result of immunogenicity, severe anaphylactic, with a history of nervous lesions, gastrointestinal bleeding, or hypertension.[8],[9] However, in recent years, herbal medicines have attracted more attention due to having combinations of bioactive ingredients which provide the synergistic effects in stroke.[10] Numerous pharmacological studies suggested that these herbal supplements or their corresponding products might dilate cardiocerebral vessels, suppress platelet aggregation, improve microcirculation in brain, protect against ischemic and reperfusion injury, possess neuroprotective properties, or help the tolerance of ischemic tissue to hypoxia.[11],[12] Regarding this information, in our present studies, we tried to screen out the thrombolytic efficacy of some Bangladeshi plants and also their comparative studies.

Piper betle L. (Piperaceae), Pan in Bengali, leaf possess activity such as antidiabetic, antiulcer, antiplatelet aggregation, antifertility, cardiotonic, antitumor, antimutagenic, respiratory depressant, and anthelmintic.[13] It is used to treat alcoholism, bronchitis, asthma, leprosy, dyspepsia, and antioxidative property.[14]Pterospermum acerifolium (L.) Willd (Sterculiaceae) is generally recognized as Kanakchampa, traditionally used for hemostasis, inflammation, ear pain, stomach ache, blood troubles, smallpox, leucorrhea, leprosy, ulcer, and tumors and as an antihyperglycemic agent, laxative, and anthelmintic.[15]Saraca indica (Caesalpiniaceae), Ashoka in Bengali, is useful as a heart tonic, hypoglycemic agent, in the treatment of abdominal pain, tumors, AIDS, inflammation, and cancer.[16]Argyreia speciosa Linn. (Convolvulaceae) is widely distributed species in different parts of India. It has been reported to possess nootropic, aphrodisiac, immunomodulatory, hepatoprotective, antioxidant, anti-inflammatory, antihyperglycemic, antidiarrheal, antimicrobial, antiviral, nematocidal, antiulcer, anticonvulsant, analgesic, and central nervous system depressant activities.[17] The leaves of A. speciosa are emollient, vesicant, stimulant, and rubefacient and are traditionally used in the treatment of various skin diseases. The roots are beneficial in anemia, diabetes, obesity, syphilis, tuberculosis, cerebral disorders, and ulcer wound and are also used as aphrodisiac, anti-inflammatory, brain-tonic, cardiotonic, expectorant, digestive, carminative, and appetizer.[18]Rhaphidophora glauca (Wall.) Schott (Araceae) is found in Alutila, Khagrachari, Bangladesh. Literature showed that it is also available in Himalaya, Nepal, Mawlibhibazar (Syhlet, Bangladesh), etc., R. glauca enlisted as “New plant species and record of Bangladesh,” which is published by Bangladesh National Herbarium, Ministry of Environment and Forest, Government of Bangladesh.[19]

This study aims to investigate the ethanolic extracts of five Bangladeshi medicinal plants viz. P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca for their clot lysis (thrombolytic activity) properties and cytotoxic properties by using in vitro models.

   Materials and Methods Top

Plant collection and identification

Leaves of P. betle (Accession No. 30853) were collected from the local market, leaves of P. acerifolium (Accession No. 30316) and S. indica (Accession No. 30726) were collected from the local area in Chittagong, whole plants of A. speciosa (Accession No. 30286) were collected from Hathazari, Chittagong and leaves of R. glauca (Accession No. 31862) were collected from Alutila, Khagrachari. The plants were authenticated as P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca by Dr. Shaikh Bokhtear Uddin, Taxonomist and Associate Professor, Department of Botany, University of Chittagong. The sample specimens of the identified plants have been preserved in the national herbarium with the mentioned accession numbers.

Chemicals and reagents

The test suspension was prepared by adding 5 ml sterile distilled water to the commercially available lyophilized SK vial (Durakinase, Dongkook Phama., Co., Ltd., South Korea) of 1,500,000 I.U. and mixed properly. This suspension was used as a stock from which 100 μl (30,000 I.U) was used for in vitro thrombolysis. Absolute ethanol (99.50%) and vincristine sulfate (VS) were purchased from Sigma-Aldrich, Munich, Germany.

Preparation of extracts

For the preparation of extracts, plant materials were air dried perfectly. Plant materials were washed properly. Then, it was chopped into small pieces and air dried for 7 days. After drying, plant powder was made by grinding. The plant materials were soaked into distilled organic solvents for 8 days. Within 10 days, the filtration is repeatedly done for 5 times with the interval of 2 days in a controlled temperature at (25°C ± 0.5°C). For the filtration, cheesecloth and Whatman filter paper number 1 was used and concentrated under reduce pressure at the temperature below 50°C using rotatory evaporator (RE 200, Bibby Sterling Ltd., UK). The concentrated extract was collected in glass petri dishes (90 mm × 15 mm, Pyrex, Germany) and allowed to dry for the complete evaporation of solvent at 37°C. The amount of extract found after extraction and their physical appearances are shown in [Table 1]. These concentrated extracts were used to investigate the antithrombotic activity of mentioned medicinal plants. A 100 mg each of the extracts was suspended in 10 ml distilled water, and the suspension was shaken vigorously on a vortex mixer. The suspension was kept overnight and decanted to remove the soluble supernatant, which was filtered through a 0.22 µm syringe filter. A 100 µl of this aqueous preparation was added to the microcentrifuge tubes containing the clots to check thrombolytic activity.[9] The same concentration (10 mg/ml) of extracts was prepared for screening the cytotoxic properties.
Table 1: Different extracts of Piper betle, Pterospermum acerifolium, Saraca indica, Argyreia speciosa, and Rhaphidophora glauca and their physical properties

Click here to view

Antithrombotic effects

Blood specimen

From ten healthy human volunteers, 4 ml of whole blood was drawn without a history of oral contraceptive or anticoagulant therapy using a protocol approved by the Institutional Ethics Committee of Chittagong University. An earlier consent, approval number HET-CU2014/1, was taken from the faculty of medicine, University of Chittagong, for the collection of blood samples from Human volunteers. A 500 μl of blood was transferred to each of the seven previously weighed microcentrifuge tubes to form clots.

Consent of informed donor

A consent form with research project title, name, and details of investigators contacts as well as the purpose of the research were supplied to the volunteer donors. They were also supplied the detail description of the inclusion and exclusion criteria of the donors, whether donors will receive any therapy or not, the volume of blood to be taken, possible discomfort of the puncture sites, and time required for blood sampling. The explanation was made on if future use of the research data beyond the current study is anticipated, whether this is a focus group if so the principal investigator should put a procedure in place in which the researchers caution people about the limit on confidentiality. Access to research information is regarding who would have access to the collected sample, information regarding retention of sample and schedules for their disposal were also detailed. It was indicated to the consent form that the volunteers might refuse to donate blood at any time. Donor whether could withdraw his sample data was disclosed. The sample was restricted for that individual study not for future research projects was presented in the consent form. Possible complications, for example, the possibility of bruising or swelling while giving blood or any other discomforts at the site where blood is drawn and that there might be minimal chance of infection and that these discomforts were brief and transient were also informed. The potential benefits of this study, not directly of the donors, but the society in general or individuals with a similar condition might be benefitted from the results of the study was explained. Confidentiality statement was included in the consent form in the way that confidentiality will be respected and no information that discloses the identity of the participant will be released or published without consent unless required by law of states. The signatures with the date of the donors were also included in the consent form.

Determination of clot lysis

Clot lysis approaches were carried out as reported earlier.[20] A 4 ml venous blood drawn from the healthy volunteers was distributed in ten different preweighed sterile microcentrifuge tubes (0.5 ml/tube) and incubated at 37°C for 45 min. After clot formation, serum was completely removed without disturbing the clot and each tube having clot was again weighed to determine the clot weight (clot weight = weight of clot containing tube – weight of the tube alone). About 100 μl of different extracts of P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca were added separately. As a positive and negative control, 100 μl of SK and distilled water, respectively, were added separately. All the tubes were then incubated at 37°C for 90 min and observed for clot lysis. The released fluid was removed and tubes were again weighed to observe the difference in weight after clot disruption. Difference obtained in weight taken before and after clot lysis was expressed as a percentage of clot lysis. The experiment was repeated with the blood samples of the informed donors.

Cytotoxicity assay

Brine shrimp bioassay was carried out to investigate the cytotoxicity of the extracts.[21] to investigate the cytotoxicity of the extracts. The dried extract preparations were re-dissolved in dimethyl sulfoxide to obtain a solution of 10 mg/ml which was subjected to serial dilution to get the concentrations between 20 μg/ml and 800 μg/ml. A 5.0 ml of artificial seawater was added to all the test tubes. Simple zoological organism (Artemia salina) was used as a convenient monitor for cytotoxic screening. The eggs of the brine shrimps were collected from the Institute of Marine Science and Fisheries, University of Chittagong, Bangladesh, and hatched in artificial seawater (prepared by using sea salt 38 g/L and adjusted to pH 8.5 using 1N NaOH) under constant aeration for 24 h under the light. The hatched shrimps were allowed to grow by 48 h to get shrimp larvae called nauplii. After 48 h, active nauplii were attracted to one side in a glass petri dish by using a micropipette. The nauplii were then separated from the eggs by allocating them in another glass petri dish containing artificial seawater and used for the assay. Suspension containing twenty nauplii was added to each test tube and was incubated at room temperature (25°C ± 1°C) for 12 h under the light. The tubes were then examined after 24 h and the number of surviving larvae in each tube was counted with the aid of a × 3 magnifying glass. Experiments were conducted along with VS in a set of three tubes per dose. The concentration that would kill 50% of the nauplii lethal concentration 50 (LC50) was determined from a linear regression equation using the software “BioStat-2009.”

Statistical analysis

All the data were shown as a mean ± standard deviation and statistical analysis was performed using paired t-test analysis and one-way analysis of variance followed by Tukey multiple comparison test with P < 0.05 taken as significant (GraphPad Prism 5.0, GraphPad Software, Inc, USA) for thrombolytic assay. LC50 values by VS and extracts was tested by the paired t-test analysis using the software SPSS, version 19.0 (SPSS for Windows, Version 18.0, IBM Corporation, NY, USA).

Percentage clot lysis = (weight of the clot after lysis by sample and removal of serum/weight of the clot before lysis by sample) ×100.

   Results Top

As described in [Table 2], different organic extracts of five medicinally important plants were used for the investigation of antithrombotic effects in human blood sample. In this approach, addition of 100 μl SK (30,000 I.U.) to the clots and subsequent incubation for 90 min at 37°C showed 79.32% ±1.62% clot lysis. On the other hand, distilled water was treated as negative control which showed only 5.86% ±0.30%, a negligible clot lysis. The mean difference in clot lysis percentage between positive and negative control was very significant (P < 0.0001 and <0.05, respectively). The most significant (P < 0.0001) clot lysis activity was observed in the ethanol extract of S. indica (49.70% ±1.69%) among the other extracts. R. glauca were showed 43.80% ±0.91% of clot lysis and its P < 0.0001. P. acerifolium and A. speciosa were showed 40.50% ±0.94% and 35.81% ±0.86%, respectively, which was almost similar and also offered significant (P < 0.0001 and 0.05, respectively) clot lysis. P. betle also showed 31.58% ±0.76% and gave the significant (P < 0.0001) clot lysis activity. Again, all the effects of the crude extracts including the positive and negative control were subjected to further comparative based study, where the multiple comparison test was done by Tukey post hoc analysis. From the analysis, it was found that SK showed the most significant effect in comparison to others. In the case of plant extracts, S. indica showed the most significant effect in comparison to other plant and negative control group, but moderate significant (P < 0.01) in the case of R. glauca, Again, R. glauca and P. acerifolium showed the most significant effect in comparison to P. betle and negative control group but not significant when compared to each other. Yet again, A. speciosa showed a significant effect in comparison to negative control but not significant to P. betle where P. betle showed the only significant effect with negative control. The comparative results in a summary are shown in [Figure 1].
Table 2: Effect of herbal extracts on in vitro clot lysis

Click here to view
Figure 1: Clot lysis by streptokinase, water, and various organic extracts. Maximum clot lysis (79.32% ±1.62%) was observed in clot treated with streptokinase. Among herbal drugs, the ethanol extract of Saraca indica showed highest significant (P < 0.05 and P < 0.0001) clot lysis activity viz., 49.70% ±1.69%. Sterile distilled water (as a negative control) showed 5.86% ±0.30% clot lysis. Values are mean ± standard deviation, (n = 10); #P < 0.0001 (two-tailed, processed by paired t-test analysis); ***P < 0.0001, **P < 0.01, resulted by one-way analysis of variance followed by Tukey multiple comparison test

Click here to view

The regression analysis for brine shrimp bioassay was presented in [Table 3]. The comparative mortality of brine shrimp and LC50 values of different extract are rendered in [Figure 2] and [Figure 3], respectively. No extract is discovered for being significantly toxic in comparison with positive control.
Table 3: Calculation of lethal concentration 50 values, confidence limits, regression equations, and Chi-square values for different extracts with reference to vincristine sulfate

Click here to view
Figure 2: Brine shrimp mortality by vincristine sulfate and different organic extracts. Percent mortality of brine shrimps of five plant extracts and standard cytotoxic agent vincristine sulfate. Data are shown as a mean ± standard deviation of ten shrimps for each concentration. Mortality achieved by the extracts of Piper betle, Pterospermum acerifolium, Saraca indica, Argyreia speciosa, Phaphidophora glauca are lower than that by vincristine sulfate. Data were processed with Tukey%s post hoc test for multiple comparisons, SPSS for Windows, version 18.0, P < 0.05 from each other

Click here to view
Figure 3: Brine shrimp lethality by vincristine sulfate and different organic extracts. Lethal concentration 50 of vincristine sulfate and different organic extracts for brine shrimp nauplii (Artemia salina). Data are shown as a mean ± standard deviation of ten shrimps for each concentration. Mortality achieved by the extracts of Piper betle. Pterospermum acerifolium, Saraca indica, Argyreia speciosa, and Rhaphidophora glauca showed lethal concentration 50 values 274.64 ± 3.46, 215.60 ± 4.59, 478.40 ± 6.98, 233.37 ± 2.56, and 209.32 ± 1.98 μg/ml, respectively, with reference to vincristine sulfate (lethal concentration 50, 0.05 ± 0.34). The data were processed with Tukey%s post hoc test for multiple comparisons, SPSS for Windows, version 18.0, P < 0.05 from each other

Click here to view

   Discussion Top

It is well known that the incidence of cardiovascular disease (CVD) remains the leading cause of death, with high morbidity and mortality.[22] However, the management of major risk aspects with conventional drugs is effective in reducing cardiovascular events, and this is supported by extensive evidence from clinical trials.[23] Some are modified further with the use of recombinant technology [24] to make these thrombolytic drugs more site specific and effective. Side effects related to these drugs have been reported that lead to further complications.[25] Recently, there exists growing awareness of the place of dietary factors and herbal supplements for the prevention of CVD and also the chance for their use within the treatment. A lot of this interest centers around the antioxidant vitamins as well as the antioxidant properties of food constituents and herbal materials, but some herbal materials can also improve conventional cardiovascular risk factors or have antithrombotic effects.[26],[27] Herbal preparations, if taken in the appropriate dose, can lead to a better option for curing various ailments. In our study of thrombolysis, we have tried five herbal extracts that have been used since ancient times for various diseases. The comparison of positive control with negative control in our thrombolytic assay, it was undoubtedly confirmed that if water was added to the clot, clot dissolution does not occur. When compared with the clot lysis percentage obtained through SK and water, a significant (P < 0.05 and P < 0.0001) thrombolytic activity was observed after treating the clots with P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca extracts. Ethanol extract of S. indica showed relatively higher thrombolytic activity among the selected plants. P. acerifolium and R. glauca were also shown a significant effect but lower than S. indica. However, it could be suggested that S. indica, R. glauca, and P. acerifolium can be a promising source of natural drug which has shown a commendable antithrombotic activity.

Toxicity of plant materials is a major concern to scientists and medical practitioners.[28],[29] Brine shrimp toxicity is a universal bioassay that perceives a broad range of biological activities and a variety of chemical structures. One basic principle is that toxicology is the deal with the pharmacology of a drug with higher doses. If any toxic compound process nontoxic at a lower, dose might elicit a useful, pharmacological, and perturbation on a physiologic system.[30] In all-purpose, the lesser the LC50 value, the more toxic the chemical is. The reverse is also true: The larger the LC50 value, the lower the toxicity. Again, a great [31] correlation (r = 0.85; P < 0.05) relating to the LC50 with the brine shrimp lethality ensure that the acute oral toxicity assay in mice. The correlation demonstrated that brine shrimp lethality LC50 < 10 μg/ml (LD50 between 100 and 1000 mg/kg) is regarded as being the cutoff value of cytotoxicity. Based on our study, compared to the positive control, no extract was found to have significant toxicity. However, the toxicity of the crude plant extracts is recognized to the phytoconstituents present in them. Moreover, with the age of the plant, intraspecies variation and time of the season, locality, extraction method used and length of storage time presence, and length of storage time usually vary the concentration of bioactive ingredients.[32]

   Conclusion Top

Our study found a significant thrombolytic activity for P. betle, P. acerifolium, S. indica, A. speciosa, and R. glauca plant which may provide a therapeutic approach for the treatment of thrombosis. However, further studies are needed to be undertaken to identify certain structures of the ingredients in the extracts and to elucidate the precise mechanism of action.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest

   References Top

Owens AP 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010;104:432-9.  Back to cited text no. 1
Kim HK, Jung H, Cho J, Huh S, Lee JM, Kim YW. Therapeutic outcomes and thromboembolic events after treatment of acute arterial thromboembolism of the upper extremity. Ann Vasc Surg 2015;29:303-10.  Back to cited text no. 2
Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: Opportunities and challenges. Arterioscler Thromb Vasc Biol 2015;35:1056-65.  Back to cited text no. 3
Chakrabarti R, Das SK. Advances in antithrombotic agents. Cardiovasc Hematol Agents Med Chem 2007;5:175-85.  Back to cited text no. 4
Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914-8.  Back to cited text no. 5
Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Des 2003;9:2337-47.  Back to cited text no. 6
Weitz JI, Crowther MA. New anticoagulants: Current status and future potential. Am J Cardiovasc Drugs 2003;3:201-9.  Back to cited text no. 7
Min SK, Han SM, Kim HT, Kwon OC, Lee S, Kim JK. Algal fucoidan, unlike heparin, has thrombolytic activity in a murine arterial thrombosis model. Blood Coagul Fibrinolysis 2012;23:359-66.  Back to cited text no. 8
Rahman MA, Sultana R, Bin Emran T, Islam MS, Rahman MA, Chakma JS, et al. Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis and cytotoxicity. BMC Complement Altern Med 2013;13:25.  Back to cited text no. 9
Zhang J, Li Y, Chen X, Pan Y, Zhang S, Wang Y. Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention. PLoS One 2014;9:e102506.  Back to cited text no. 10
Feigin VL. Herbal medicine in stroke: Does it have a future? Stroke 2007;38:1734-6.  Back to cited text no. 11
Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, et al. Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 2007;38:1973-9.  Back to cited text no. 12
Rai MP, Thilakchand KR, Palatty PL, Rao P, Rao S, Bhat HP, et al. Piper betel Linn (betel vine), the maligned Southeast Asian medicinal plant possesses cancer preventive effects: Time to reconsider the wronged opinion. Asian Pac J Cancer Prev 2011;12:2149-56.  Back to cited text no. 13
Paranjpe R, Gundala SR, Lakshminarayana N, Sagwal A, Asif G, Pandey A, et al. Piper betel leaf extract: Anticancer benefits and bio-guided fractionation to identify active principles for prostate cancer management. Carcinogenesis 2013;34:1558-66.  Back to cited text no. 14
Paramaguru R, Mazumder PM, Sasmal D, Jayaprakash V. Antidiabetic activity of Pterospermum acerifolium flowers and glucose uptake potential of bioactive fraction in L6 muscle cell lines with its HPLC fingerprint. Biomed Res Int 2014;2014:459376.  Back to cited text no. 15
Viswanatha Swamy AH, Patel UM, Koti BC, Gadad PC, Patel NL, Thippeswamy AH. Cardioprotective effect of Saraca indica against cyclophosphamide induced cardiotoxicity in rats: A biochemical, electrocardiographic and histopathological study. Indian J Pharmacol 2013;45:44-8.  Back to cited text no. 16
Galani VJ, Patel BG, Patel NB. Argyreia speciosa (Linn. f.) sweet: A comprehensive review. Pharmacogn Rev 2010;4:172-8.  Back to cited text no. 17
Yadav KS, Yadav NP, Rawat B, Rai VK, Shanker K, Venkateswara Rao C. An assessment of wound healing potential of Argyreia speciosa leaves. ScientificWorldJournal 2014;2014:406921.  Back to cited text no. 18
Boyce P. Plate 377. Rhaphidophora glauca . Curtis's Botanical Magazine 1999;16:273-80.  Back to cited text no. 19
Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Daginawala HF. Development of an in vitro model to study clot lysis activity of thrombolytic drugs. Thromb J 2006;4:14.  Back to cited text no. 20
Shah SM, Sadiq A, Shah SM, Khan S. Extraction of saponins and toxicological profile of Teucrium stocksianum boiss extracts collected from district Swat, Pakistan. Biol Res 2014;47:65.  Back to cited text no. 21
Park IS, Lee HW, Ryuk JA, Ko BS. Effects of an aqueous extract of dangguijagyagsan on serum lipid levels and blood flow improvement in ovariectomized rats. Evid Based Complement Alternat Med 2014;2014:497836.  Back to cited text no. 22
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): Case-control study. Lancet 2004;364:937-52.  Back to cited text no. 23
Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000;109:52-8.  Back to cited text no. 24
Baruah DB, Dash RN, Chaudhari MR, Kadam SS. Plasminogen activators: A comparison. Vascul Pharmacol 2006;44:1-9.  Back to cited text no. 25
Yang Y, Chan SW, Hu M, Walden R, Tomlinson B. Effects of some common food constituents on cardiovascular disease. ISRN Cardiol 2011;2011:397136.  Back to cited text no. 26
Chen ST, Maruthur NM, Appel LJ. The effect of dietary patterns on estimated coronary heart disease risk: Results from the dietary approaches to stop hypertension (DASH) trial. Circ Cardiovasc Qual Outcomes 2010;3:484-9.  Back to cited text no. 27
Singh A, Singh SK. Molluscicidal evaluation of three common plants from India. Fitoterapia 2005;76:747-51.  Back to cited text no. 28
Molla E, Giday M, Erko B. Laboratory assessment of the molluscicidal and cercariacidal activities of Balanites aegyptiaca. Asian Pac J Trop Biomed 2013;3:657-62.  Back to cited text no. 29
Nguta JM, Mbaria JM. Brine shrimp toxicity and antimalarial activity of some plants traditionally used in treatment of malaria in Msambweni district of Kenya. J Ethnopharmacol 2013;148:988-92.  Back to cited text no. 30
Arcanjo DD, Albuquerque AC, Melo-Neto B, Santana LC, Medeiros MG, Citó A. Bioactivity evaluation against Artemia salina Leach of medicinal plants used in Brazilian Northeastern folk medicine. Braz J Biol 2012;72:505-9.  Back to cited text no. 31
Muregi FW, Chhabra SC, Njagi EN, Lang'at-Thoruwa CC, Njue WM, Orago AS, et al. Anti-plasmodial activity of some Kenyan medicinal plant extracts singly and in combination with chloroquine. Phytother Res 2004;18:379-84.  Back to cited text no. 32

   Authors Top

Mir Muhammad Nasir Uddin, in currently working as a faculty member at Department of pharmacy, University of Chittagong, Chittagong, Bangladesh. He obtained Pharm D in 2009 from the University college of Pharmacy, University of the Punjab, Lahore, Pakistan. He also achieved M.Phil. (Pharmacogenetics and Pharmacokinetcs) in 2013 from Department of Pharmacology and Clinical Pharmacy, University of Dhaka. His current research is focused on personalized medicine & pharmacogenomics.


  [Figure 1], [Figure 2], [Figure 3]

  [Table 1], [Table 2], [Table 3]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Materials and Me...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded79    
    Comments [Add]    

Recommend this journal